Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The proposed 3-week, double-blind, crossover, proof of concept study aims to manipulate
neurochemical dysfunctions characteristic of individuals with co-occurring BD and AUD (i.e.,
abnormally low prefrontal GABA and glutamate), using medications that have been shown to
normalize cortical GABA (i.e., gabapentin) and glutamate (i.e., NAC) levels in past research,
and to evaluate medication-related changes in response inhibition and alcohol cue-reactivity
fMRI tasks as well as drinking and mood in individuals with AUD+BD.
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborators:
National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institutes of Health (NIH)